Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025
Eli Lilly and Company stock (NYSE: LLY) remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand. In early trading on Tuesday, Dec. 16, Eli Lilly shares hovered around the $1,050 area, after a year that included the company becoming the first drugmaker to reach a $1 trillion market value—a milestone that underscored how central Lilly’s metabolic franchise has become to investors.